Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease (2019)

First Author: Catt H
Attributed to:  North West HTMR funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s40273-019-00826-0

Publication URI: http://dx.doi.org/10.1007/s40273-019-00826-0

Type: Journal Article/Review

Parent Publication: PharmacoEconomics

Issue: 12